Sponsor: Viracta Therapeutics, Inc.
Sponsor Study ID: VT3996-202
Study Title: An Open Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein Barr Virus Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL 1)
CTO #: 103365
NCT Number: NCT05011058
Phase: II
Protocol Type: Treatment
Age Group: Both
Disease Sites: Other Hematopoietic
Study Objectives: A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas.